Umaima is CEO and co-founder of 52North, a multi-award winning med-tech company focused on reinventing the healthcare journey, starting by transforming cancer care with Neutrocheck®. In 2023, 52North became the first ever venture investment of Macmillan Cancer Support.

In 2022, Umaima was recognised on Management Today’s 35 under 35 Women in Business. She is also a Non-Executive Director at Health Tech Enterprise and the Pharmaceutical Licensing Group, Editor of the Business Development and Licensing Journal, and a trustee at Cambridge Community Arts.

A former business development professional and banking lawyer, Umaima is a seasoned negotiator of significant M&A and licensing transactions with values in the billions of dollars, involving pharmaceutical assets across multiple therapy areas which have had significant tangible impact on patient treatment pathways and health outcomes.
Umaima is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge. She is passionate about business, innovation, commercialising science, championing women to pursue STEM subjects and careers, and continuous learning.